Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 3, 2001, Pages 266-273

  Duwe, Susanne ^a,b   Brunn, Monika ^a   Altmann, Doris ^a   Hamouda, Osamah ^a   Schmidt, Barbara ^c   Walter, Hauke ^c   Pauli, Georg ^a   Kücherer, Claudia ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Drug resistance; Genotypic; HIV 1; Phenotypic; Primary resistance; Therapy naive seroconverter

Indexed keywords

NUCLEOSIDE ANALOG; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; FOLLOW UP; GENOTYPE; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROCONVERSION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 0035280397     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200103010-00010     Document Type: Article

References (34)

1. Mutations in retroviral genes associated with drug resistance
2. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine
3. Genetic correlates of in vivo viral resistance to the HIV-1 protease indinavir
4. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society - USA Panel
5. Overview of prevalence of HIV drug resistance in antiretroviral inexperienced patients in Europe
6. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
7. HIV-1 drug resistance in newly infected individuals
8. Transmission of antiretroviral-drug-resistant HIV-1 variants
9. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel
10. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
11. Transmission of HIV-1 resistant to multiple reverse transcriptase and protease inhibitors
12. Einflussgrössen und verlauf der HIV-1 infektion-serokonverterstudie
13. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors
14. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing
15. Neutralisation sensitivity of cell culture-passaged simian immunodeficiency virus
16. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy
17. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
18. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
19. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudine
20. Zidovudine resistant human immunodeficiency virus selected by passage in cell culture
21. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconverters infected with zidovudineresistant variants
22. Fitness of HIV-1 RT mutant: Is Muller's ratchet operational?
23. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
24. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
25. The same mutation that encodes low level human immunodeficiency virus type 1 resistance to 2′, 3′-dideoxyinosine and 2′, 3′-dideoxycytidine confers high-level resistance to the (-) anantiomer of 2′, 3′-dideoxy-3′-thiacytidine
26. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptase by the phenyl ethyl thiozolyl thiourea derivatives trovirdine and MSG-127
27. Comparative rates of in vitro resistance development of HIV-1 to non-nucleoside analog RT inhibitors
28. Comprehensive analysis of HIV-1 variants individually selected for resistance to six protease inhibitors
29. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease
30. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1 infected antiviral-naive patients
31. Indication for increasing prevalence of resistance mutations for protease inhibitors in therapy-naive HIV-1-positive German patients
32. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
33. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
34. Selected secondary mutations in the protease region can be independent predictors of virological failure in antiretroviral-naive patients treated with protease inhibitor-containing HAART regimens